{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:47:40Z","timestamp":1772034460070,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2018.00810","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T04:24:14Z","timestamp":1547699054000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Active Moderate-to-Severe Graves' Orbitopathy in a Patient With Type 2 Diabetes Mellitus and Vascular Complications"],"prefix":"10.3389","volume":"9","author":[{"given":"Francesca","family":"Urselli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilda","family":"Pontieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Peschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Liccardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Rita","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on graves' orbitopathy guidelines for the management of graves' orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"B4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/bjo.83.4.463","article-title":"Diabetes mellitus: a risk factor in patients with Graves' orbitopathy","volume":"83","author":"Kalmann","year":"1999","journal-title":"Br J Opthalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4239\/wjd.v6.i1.67","article-title":"Type 1 diabetes and polyglandular autoimmune syndrome: a review","volume":"6","author":"Hansen","year":"2015","journal-title":"World J Diabetes"},{"key":"B6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.numecd.2015.01.003","article-title":"Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy","volume":"25","author":"Le Moli","year":"2015","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"B7","article-title":"Diabetes mellitus","volume-title":"Ellenberg and Rifkin's Diabetes Mellitus: Theory and Practice","author":"Unger","year":"1990"},{"key":"B8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-2415-7-8","article-title":"Thiazolidinedione induced thyroid associated orbitopathy","volume":"7","author":"Lee","year":"2007","journal-title":"BMC Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1089\/thy.2017.0338","article-title":"Biguanides metformin and phenformin generate therapeutic effects via AMP-activated protein kinase\/extracellular-regulated kinase pathways in an in vitro model of Graves' orbitopathy","volume":"28","author":"HanYE","year":"2018","journal-title":"Thyroid"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1210\/jc.2012-2758","article-title":"Efficacy and safety of orbital radiotherapy for Graves' orbitopathy","volume":"97","author":"Tanda","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1210\/jc.2003-030260","article-title":"Long-term safety of orbital radiotherapy for Graves' ophthalmopathy","volume":"88","author":"Marcocci","year":"2003","journal-title":"Clin Endocrinol Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves' orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12020-014-0283-1","article-title":"Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy","volume":"48","author":"Savino","year":"2015","journal-title":"Endocrine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1530\/EJE-16-0552","article-title":"Rituximab therapy for Graves' orbitopathy \u2013 lessons from randomized control trials","volume":"176","author":"Stan","year":"2017","journal-title":"Eur J Endocrinol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jcjo.2017.07.009","article-title":"Role of methotrexate in thyroid-related orbitopathy","volume":"53","author":"Rubinov","year":"2017","journal-title":"Can J Ophthalmol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4172\/2155-9570.1000422","article-title":"Methotrexate as a corticosteroid-sparing agent for thyroid eye disease","volume":"6","author":"Rivera-Grana","year":"2015","journal-title":"J Clin Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ajoc.2017.07.001","article-title":"Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy","volume":"7","author":"Russel","year":"2017","journal-title":"Am J Ophthalmol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/thy.2009.0278","article-title":"A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts","volume":"20","author":"Kumar","year":"2010","journal-title":"Thyroid"},{"key":"B20","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1089\/105072501753210984","article-title":"Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy","volume":"11","author":"Jyonouchi","year":"2001","journal-title":"Thyroid"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40618-018-0943-8","article-title":"Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy","volume":"41","author":"Marin\u00f2","year":"2018","journal-title":"J Endocrinol Invest."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1210\/jcem.85.1.6257","article-title":"Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial","volume":"85","author":"Kahaly","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"B24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00417-009-1214-3","article-title":"A retrospective study on the efficacy of total absorbed orbital doses of 12, 16 and 20 Gy combined with systemic steroid treatment in patients with Graves' orbitopathy","volume":"248","author":"Johnson","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2018.00810\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T04:24:16Z","timestamp":1547699056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2018.00810\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":24,"alternative-id":["10.3389\/fendo.2018.00810"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2018.00810","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"article-number":"810"}}